NICE Recommends First Vitiligo Treatment for Use in the NHS
The National Institute for Health and Care Excellence (NICE) has issued a positive recommendation for the first licensed treatment for vitiligo to be used in the NHS, providing a new option for more than 80,000 people in England living with the condition. Vitiligo is a chronic autoimmune disorder in which the immune system attacks melanocytes, the cells responsible for skin pigmentation. This leads to pale or white patches on the skin, which can have a considerable effect on
American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium 2026 | iPharmaCenter
Keytruda and Welireg Combination Cuts Risk of RCC Recurrence by 28% in Adjuvant Setting Merck reported new Phase 3 results from the LITESPARK-022 trial showing that adding Welireg (belzutifan) to Keytruda (pembrolizumab) as adjuvant therapy significantly reduced the likelihood of recurrence or death in certain patients with clear cell renal cell carcinoma (RCC) following nephrectomy. The study demonstrated a 28% lower risk of disease recurrence or death compared with Keytruda
Novo Nordisk to Slash U.S. List Prices for Semaglutide Portfolio from 2027 Amid Rising Competitive Pressure
Novo Nordisk Semaglutide Price Cut 2027: Wegovy & Ozempic List Price Drops to $675 Amid Eli Lilly Zepbound Competition Novo Nordisk announced that it will cut the U.S. list price of its leading semaglutide‑based medicines, Wegovy, Ozempic, and Rybelsus, to $675 per month starting January 2027, marking a significant step to improve affordability and access to GLP‑1 therapies for obesity and type 2 diabetes The price reduction, representing up to 50% off for Wegovy and 35% for
Top 10 Pharmaceutical Companies by Revenue 2025: Best-Selling Drugs Analysis | iPharmaCenter
Top pharmaceutical companies by revenues in 2025. The revenues are captured from the official websites of pharmaceutical companies
CagriSema misses non‑inferiority vs tirzepatide in REDEFINE 4; Novo Nordisk shares fall 15% | iPharmaCenter
CagriSema produced large absolute weight loss in REDEFINE 4 but failed its main goal of matching Eli Lilly’s tirzepatide, raising questions about its competitive positioning in obesity. CagriSema delivers strong weight loss, but not enough vs tirzepatideIn the open‑label phase 3 REDEFINE 4 trial, adults with obesity and at least one comorbidity were randomized to once‑weekly CagriSema (fixed‑dose cagrilintide 2.4 mg plus semaglutide 2.4 mg) or tirzepatide 15 mg, both given su
Novartis Advances Remibrutinib Toward FDA Approval in Chronic Inducible Urticaria | iPharmaCenter
Does Novartis remibrutinib work for chronic inducible urticaria? Yes, first Phase III success in 3 CIndU types Oral remibrutinib hit primary endpoint vs. placebo at week 12 in RemIND trial, with complete responses in symptomatic dermographism, cold urticaria, and cholinergic urticaria. Rhapsido CIndU approval status Novartis seeks FDA approval for dermographism (most common form of CIndU). Why This Matters First targeted therapy for CIndU, affecting ~29M adults worldwide Sa